Amgen and UCB report positive Phase III BRIDGE study results of romosozumab to treat osteoporosis

Amgen and UCB have reported positive results from its Phase III BRIDGE study of romosozumab for treating men with osteoporosis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news